Intellectual Property In India: Novartis Sees Patent Protections To Be In Patients' Best Interests (Part 3 of 3)
This article was originally published in PharmAsia News
Executive Summary
Ultimately, Novartis' lawsuit and the Mashelkar Commission's findings have inflamed political and economic factions over what is in India's "national interest" - maintaining access to low-cost drugs for India's poor, or creating a foreign investment-friendly environment in India by bringing its intellectual property infrastructure on par with other nations
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)